Indexată BDI | IDB Indexed
A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.
RJR și SRR oferă anual Premiul Național pentru Știință și Cercetare - pentru autorii celor mai bune articole științifice publicate [...]
Tema plagiatului este tot mai mult discutată în ultima vreme. Apariția unor programe performante de căutare și identificare a similitudinilor între texte [...]
CONSIDERATIONS ABOUT BIOLOGIC TREATMENT WITHDRAWAL IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS AFTER DISEASE REMISSION
The aim of this paper is to discuss the reasons and opportunities for tapering and discontinuing treatment with biological agents when the clinical remission of juvenile idiopathic arthritis (JIA) is achieved. Unfortunately, the few studies published recently on JIA focused almost exclusively on etanercept and had conflicting results. It appears that the relapse rates after termination of these medications is substantial. No predictors of the risk of flare were identified. Currently, the role of Doppler ultrasound in the assessment of the status of JIA (activity/remission) has not been fully established. The optimal timeline for withdrawal after documentation of remission, as much as the modality of discontinuation, also remain to be established. The lack of evidence-based data from randomized controlled clinical trials imposes a pressing need to create guidelines for treatment discontinuation.
Keywords: JIA, biological treatment, withdrawal
Full text | PDF